Abstract
The progress achieved in the field of genomics in recent years is leading medicine to adopt a personalized model in which the knowledge of individual DNA alterations will allow a targeted approach to cancer. Using pancreatic cancer as a model, we discuss herein the fundamentals that need to be considered for the high throughput and global identification of mutations. These include patient-related issues, sample collection, DNA isolation, gene selection, primer design, and sequencing techniques. We also describe the possible applications of the discovery of DNA changes to the approach of this disease and cite preliminary efforts where the knowledge has been translated into the clinical or preclinical setting.
Similar content being viewed by others
References
Sanger F, Nicklen S, Coulson AR (1997) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463–5467
International Consortium completes Human Genome Project [National Human Genome Research Institute web site]. http://www.genome.gov/11006929 14 April 2003
Guttmacher AE, Collins FS (2003) Welcome to the genomic era. N Engl J Med 349:996–998
454 Life Sciences and Baylor College of Medicine Complete Sequencing of DNA Project. [454 Life Sciences website] http://www.454.com/news-events/press-releases.asp?display=detail&id=68 Accessed 31 May 2007
Wheeler DA, Srinivasan M, Egholm M et al (2008) The complete genome of an individual by massively parallel DNA sequencing. Nature 452:872–876
Kopnin BP (2000) Targets of oncogenes and tumor suppressors: key for understanding basic mechanisms of carcinogenesis. Biochemistry (Mosc) 65:2–27
Croce CM (2008) Oncogenes and cancer. N Engl J Med 358:502–511
Elledge SJ, Hannon GJ (2005) An open letter to cancer researchers. Science 310:439–441
Heng HH (2007) Cancer genome sequencing: the challenges ahead. Bioessays 29:783–794
Varmus H (2006) The new era in cancer research. Science 312:1162–1165
Sjöblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274
Cancer Sequencing Projects (CSPs) [National Human Genome Research Institute web site]. http://www.genome.gov/19517442
Weir BA, Woo MS, Getz G et al (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893–898
Collins FS, Barker AD (2007) Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 296:50–57
Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349
Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500
Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. LoS Med 2:e73
Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792
McGuire AL, Gibbs RA (2006) Genetics. No longer de-identified. Science 312:370–371
McGuire AL, Gibbs RA (2006) Currents in contemporary ethics: meeting the growing demands of genetic research. J Law Med Ethics 34:809–812
McGuire AL, Caulfield T, Cho MK (2007) Research ethics and the challenge of whole genome sequencing. Nat Rev Gen 9:152–156
Renegar G, Webster CJ, Stuerzebecker S et al (2006) Returning genetic research results to individuals: points to consider. Bioethics 20:24–36
Knoppers BM, Joly Y, Simard J et al (2006) The emergence of an ethical duty to disclose genetic research results: international perspectives. Eur J Human Gen 14:1170–1178
MacNeil S, Fernandez C (2006) Informing research participants of research results: analysis of Canadian university based research ethics board policies. J Med Ethics 32:49–54
Kohane IS, Mandi KD, Taylor PL et al (2007) Reestablishing the researcher–patient compact. Science 316:836–837
Rubin AF, Green P (2007) Comment on “the consensus coding sequences of human breast and colorectal cancers”. Science 317:1500
Getz G, Höfling H, Mesirov JP et al (2007) Comment on “the consensus coding sequences of human breast and colorectal cancers”. Science 317:1500
Mahadevan D, Von Hoff DD (2007) Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6:1186–1197
Check E (2007) Cancer atlas maps out sample worries. Nature 447:1036–1037
Compton C (2007) Getting to personalized cancer medicine: taking out the garbage. Cancer 110:1641–1643
Tu SM, Lin SH, Logothetis CJ (2002) Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 3:508–513
Woodruff MF (1983) Cellular heterogeneity in tumours. Br J Cancer 47:589–594
Kim JH, Tuziak T, Hu L et al (2005) Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab Invest 85:532–549
The Cancer Genome Atlas Biospecimen Selection Process. The Cancer Genome Atlas website. http://cancergenome.nih.gov/components/hcbcr_process.asp
Murray GI (2007) An overview of laser microdissection technologies. Acta Histochem 109:171–176
Mager SR, Oomen MH, Morente MM et al (2007) Standard operating procedure for the collection of fresh frozen tissue samples. Eur J Cancer 43:828–834
Gallegos Ruiz MI, Floor K, Rijmen F et al (2007) EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens. Cell Oncol 29:257–264
Ferrer I, Armstrong J, Capellari S et al (2007) Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: a BrainNet Europe study. Brain Pathol 17:297–303
Andreassen CN, Sørensen FB, Overgaard J et al (2004) Optimisation and validation of methods to assess single nucleotide polymorphisms (SNPs) in archival histological material. Radiother Oncol 72:351–356
Lizardi PM, Huang X, Zhu Z et al (1998) Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat Genet 19:225–232
Dean FB, Nelson JR, Giesler TL et al (2001) Rapid amplification of plasmid and phage DNA using Phi 29 DNA polymerase and multiply-primed rolling circle amplification. Genome Res 11:1095–1099
Pinard R, de Winter A, Sarkis GJ et al (2006) Assessment of whole genome amplification-induced bias through high-throughput, massively parallel whole genome sequencing. BMC Genomics 7:216
Genomic DNA Preparation from RNAlater™ Preserved Tissues [Ambion website]. (2008) http://www.ambion.com/techlib/misc/genomicDNA_rnalater.html
Catalogue of somatic mutations in cancer [Sanger Institute COSMIC website] http://www.sanger.ac.uk/genetics/CGP/cosmic/
Pancreatic Cancer Gene Database [PCGD website] http://www.bioinformatics.org/pcgdb/
Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799
Futreal PA, Coin L, Marshall M et al (2004) A census of human cancer genes. Nat Rev Cancer 4:177–183
Brentnall TA (2005) Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 6:437–445
Berger DH, Fisher WE (2002) Inherited pancreatic cancer syndromes. In: Evans DB, Pisters PWT, Abbruzzese JL (eds) M.D. Anderson solid tumor oncology series-pancreatic cancer. Springer, New York, pp 73–82
Logsdon CD, Simeone DM, Binkley C et al (2003) Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63:2649–2657
Buchholz M, Kestler HA, Bauer A et al (2005) Specialized DNA arrays for the differentiation of pancreatic tumors. Clin Cancer Res 11:8048–8054
Higgins ME, Claremont M, Major JE et al (2007) CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res 35:D721–D726
Resequencing Resource http://cbio.mskcc.org/cancergenes/index.php
Albert TJ, Molla MN, Muzny DM et al (2007) Direct selection of human genomic loci by microarray hybridization. Nat Methods 4:903–905
Hodges E, Xuan Z, Balija V et al (2007) Genome-wide in situ exon capture for selective resequencing. Nat Genet 39:1522–1527
Repeat Masker (2003) [computer program] Institute for Systems Biology http://www.repeatmasker.org/
Single Nucleotide Polymorphism database [NCBI website]. http://www.ncbi.nlm.nih.gov/projects/SNP/ Accessed 17 Jan 2008
Primer3. Howard Hughes Medical Institute [Primer3 website]. http://frodo.wi.mit.edu/ Accessed 7 Feb 2007
UCSC In-Silico PCR [UCSC Genome Bioinformatics website]. http://genome.ucsc.edu/cgi-bin/hgPcr?command=start
Parameswaran P, Jalili R, Tao L et al (2007) A pyrosequencing-tailored nucleotide barcode design unveils opportunities for large-scale sample multiplexing. Nucleic Acids Res 35:e130
Ronaghi M, Uhlén M, Nyrén P (1998) A sequencing method based on real-time pyrophosphate. Science 28:363–365
Margulies M, Egholm M, Altman WE et al (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 37:376–380
Thomas RK, Nickerson E, Simons JF et al (2006) Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12:852–855
Solexa Ltd (2004) Pharmacogenomics 5:433–438
Bennett ST, Barnes C, Cox A et al (2005) Toward the 1, 000 dollars human genome. Pharmacogenomics 6:373–382
Solexa sequencing Technology Illumina website. http://www.illumina.com/pages.ilmn?ID=203
Dutt A, Beroukhim R (2007) Single nucleotide polymorphism array analysis of cancer. Curr Opin Oncol 19:43–49
Calhoun ES, Hucl T, Gallmeier E et al (2006) Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res 66:7920–7928
Harada T, Chelala C, Bhakta V et al (2008) Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 27:1951–1960
Cargill M, Altshuler D, Ireland J et al (1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 22:231–238 (erratum Nat Genet 23:373)
Kruglyak L, Nickerson DA (2001) Variation is the spice of life. Nat Genet 27:234–236
Hinds DA, Stuve LL, Nilsen GB et al (2005) Whole-genome patterns of common DNA variation in three human populations. Science 307:1072–1079
Bernig T, Chanock SJ (2006) Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn 6:319–331
Abraham J, Earl HM, Pharoah PD, Caldas C (2006) Pharmacogenetics of cancer chemotherapy. Biochim Biophys Acta 1766:168–183
Bernig T, Chanock SJ (2006) Challenges of SNP genotyping and genetic variation: its future role in diagnosis and treatment of cancer. Expert Rev Mol Diagn 6:319–331
West CM, Elliott RM, Burnet NG (2007) The genomics revolution and radiotherapy. Clin Oncol (R Coll Radiol) 19:470–480
Imyanitov EN, Togo AV, Hanson KP (2004) Searching for cancer-associated gene polymorphisms: promises and obstacles. Cancer Lett 204:3–14
Bodmer WF, Bailey CJ, Bodmer J et al (1987) Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 19;32:614–616
Cannon-Albright LA, Goldgar DE, Meyer LJ et al (1992) Assignment of a locus for familial melanoma, MLM, to chromosome 9p13–p22. Science 258:1148–1152
Wooster R, Neuhausen SL, Mangion J et al (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 265:2088–2090
Armitage P, Doll R (1954) The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 8:1–12
Renan MJ (1993) How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7:139–146
Beckman RA, Loeb LA (2005) Genetic instability in cancer: theory and experiment. Semin Cancer Biol 15:423–435
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Venkatesan RN, Bielas JH, Loeb LA (2006) Generation of mutator mutants during carcinogenesis. DNA Repair 5:294–302
Kimchi-Sarfaty C, Oh JM, Kim IW et al (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315:525–528
McClintock D, Ratner D, Lokuge M et al (2007) The mutant form of Lamin A that causes Hutchinson-Gilford Progeria is a biomarker of cellular aging in human skin. PLoS ONE 2:e1269
Conne B, Stutz A, Vassalli JD (2000) The 3’ untranslated region of messenger RNA: a molecular “hotspot” for pathology? Nat Med 6:637–641
Duan J, Wainwright MS, Comeron JM et al (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12:205–216
Hoogendoorn B, Coleman SL, Guy CA et al (2003) Functional analysis of human promoter polymorphisms. Hum Mol Genet 12:2249–2254
Pagani F, Baralle FE (2004) Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 5:389–396
Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153–158
Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14:143–149
Hardenbol P, Yu F, Belmont J et al (2005) Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res 15:269–275
Bell PA, Chaturvedi S, Gelfand CA et al (2002) SNPstream UHT: ultra-high throughput SNP genotyping for pharmacogenomics and drug discovery. Biotechniques 74:76–77
Iplex Gold Review [Sequenom website] http://www.sequenom.com/Genetic-Analysis/Applications/iPLEX-Genotyping/iPLEX-Overview.aspx
Fan JB, Oliphant A, Shen R et al (2003) Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 68:69–78
Genechip Arrays [Affymetrix website]. http://www.affymetrix.com/products/arrays/index.affx
Gunderson KL, Steemers FJ, Lee G et al (2005) A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet 37:549–554
van der Heijden MS, Kern SE (2005) Molecular genetic alterations in cancer-associated genes. In: Von Hoff DD, Evans DB, Hruban RH (eds) Pancreatic cancer. Jones and Bartlett, Sandbury, MA, pp 31–41
Moskaluk CA, Hruban RH, Kern SE (1997) p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140–2143
Hruban RH, Wilentz RE, Kern SE (2000) Genetic progression in the pancreatic ducts. Am J Pathol 156:1821–1825
Hruban RH, Yeo CJ, Kem SE (2002) Pancreatic cancer. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer, 2nd edn edn. McGraw-Hill, New York, pp 659–673
MacLeod SL, Chowdhury P (2006) The genetics of nicotine dependence: relationship to pancreatic cancer. World J Gastroenterol 12:7433–7439
Porta M, Malats N, Jariod M et al (1999) Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. Lancet 354:2125–2129
Alguacil J, Porta M, Kauppinen T et al (2003) KRAS II Study Group. Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer. Int J Cancer 107:635–641
Larsson SC, Giovannucci E, Wolk A (2006) Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 131:1271–1283
Jiao L, Bondy ML, Hassan MM et al (2007) Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer. Cancer 109:840–848
Chen J, Li D, Wei C et al (2007) Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res 13:3100–3104
Jiao L, Hassan MM, Bondy ML et al (2007) The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett 245:61–68
Jiao L, Hassan MM, Bondy ML et al (2007) XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J Gastroenterol 16:2379–2386
Jiao L, Bondy ML, Hassan MM et al (2006) Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. Cancer Detect Prev 30:284–291
Rogers CD, Couch FJ, Brune K et al (2004) Genetics of the FANCA gene in familial pancreatic cancer. J Med Genet 41:e126
Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T et al (2006) Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 3:e516
Berthelemy P, Bouisson M, Escourrou J et al (1995) Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 123:188–191
van Heek T, Rader AE, Offerhaus JA et al (2002) K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 117:755–765
Takahashi K, Yamao K, Okubo K et al (2005) Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointest Endosc 61:76–79
Itoi T, Takei K, Sofuni A et al (2005) Immunohistochemical analysis of p53 and MIB–1 in tissue specimens obtained from endoscopic ultrasonography-guided fine needle aspiration biopsy for the diagnosis of solid pancreatic masses. Oncol Rep 13:229–234
Lohr M, Muller P, Mora J et al (2001) p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis. Gastrointest Endosc 53:734–743
Pugliese V, Pujic N, Saccomanno S et al (2001) Pancreatic intraductal sampling during ERCP in patients with chronic pancreatitis and pancreatic cancer: cytologic studies and K-ras-2 codon 12 molecular analysis in 47 cases. Gastrointest Endosc 54:595–599
Berger DH, Chang H, Wood M et al (1999) Mutational activation of K-ras in nonneoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Cancer 85:326–332
Caldas C, Hahn SA, da Costa LT et al (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27–32
Kalthoff H, Schmiegel W, Roeder C et al (2003) p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 8:289–298
Moskaluk CA, Hruban RH, Kern SE (1997) p16 and K-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140–2143
Tada M, Omata M, Kawai S et al (1993) Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 53:2472–2474
Ohtsubo K, Watanabe H, Yamaguchi Y et al (2003) Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. J Gastroenterol 38:663–671
Dong M, Ma G, Tu W et al (2003) Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. World J Gastroenterol 11:2162–2165
Yokoyama M, Yamanaka Y, Friess H et al (1994) p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 14:2477–2483
Ghaneh P, Greenhalf W, Humphreys M et al (2001) Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 8:199–208
Tascilar M, Skinner HG, Rosty C et al (2001) The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7:4115–4121
Li D, Li Y, Jiao L et al (2007) Effects of base excision repair gene polymorphisms on pancreatic cancer survival. Int J Cancer 120:1748–1754
Li D, Liu H, Jiao L et al (2006) Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival. Cancer Res 66:3323–3330
Li D, Frazier M, Evans DB et al (2006) Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 24:1720–1728
Lee J, Jang KT, Ki CS et al (2007) Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 109:1561–1569
Ueno H, Kiyosawa K, Kaniwa N (2007) Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J 97:145–151
Myers SN, Goyal RK, Roy JD et al (2006) Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet Genomics 16:315–320
Kroep JR, Loves WJ, van der Wilt CL et al (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1:371–376
Gross E, Seck K, Neubauer S et al (2003) High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism. Int J Oncol 22:325–332
Pullarkat ST, Stoehlmacher J, Ghaderi V et al (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65–70
Stoehlmacher J, Ghaderi V, Iobal S et al (2001) A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21:3075–3079
Ryu JS, Hong YC, Han HS et al (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44:311–316
Park DJ, Stoehlmacher J, Zhang W et al (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654–8658
van der Heijden MS, Brody JR, Dezentje DA et al (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508–7515
Sebti SM, Adjei AA (2004) Farnesyltransferase inhibitors. Semin Oncol 31:28–39
Van Cutsem E, van de Velde H, Karasek P et al (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438
GI-4000 for mutated-Ras mediated cancers [GlobeImmune website]. http://www.globeimmune.com/index.php
Ng SSW, Tsao MS, Chow S et al (2000) Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60:5451–5455
Moore MJ, Goldstein D, Hamm J et al (2007) National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966
Tzeng CW, Frolov A, Frolova N et al (2007) Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol 14:2150–2158
Brand RE, Lerch MM, Rubinstein WS et al (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460–1469
Canto MI (2007) Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Semin Oncol 34:295–302
Acknowledgements
The study was supported by a grant from the Effie and Wofford Cain Foundation. The authors acknowledge Dr. Yi Han for her input on the Solexa technology, Dr. Amy L. McGuire for her comments on ethical issues, Mrs. Katie Elsbury for editorial support, Mrs. Sally Hodges for her assistance with patient-related issues, and all the people at the Human Genome Sequencing Center who made this work possible.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Voidonikolas, G., Kreml, S.S., Chen, C. et al. Basic Principles and Technologies for Deciphering the Genetic Map of Cancer. World J Surg 33, 615–629 (2009). https://doi.org/10.1007/s00268-008-9851-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-008-9851-y